Overview

* Alumis ( ALMS ) Q3 net loss widens to $110.8 mln from $93.1 mln a year ago

* Company reports $2.1 mln collaboration revenue for Q3 2025

* Operating expenses rise due to increased R&D and merger costs

Outlook

* Alumis expects topline Phase 3 ONWARD data in early Q1 2026

* Company anticipates Phase 2b LUMUS data in Q3 2026

* Alumis plans Phase 2 trial for A-005 in H1 2026

Result Drivers

* INCREASED R&D EXPENSES - Alumis ( ALMS ) attributes rise in R&D expenses to increased contract research and clinical trial costs, including for envudeucitinib

* MERGER COSTS - Alumis ( ALMS ) cites merger with ACELYRIN as contributing to increased general and administrative expenses

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$110.75

Income mln

Q3 -$115.29

Income mln

From

Operatio

ns

Q3 $117.36

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy."

* Wall Street's median 12-month price target for Alumis Inc ( ALMS ) is $18.00, about 70.9% above its November 12 closing price of $5.24

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)